anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Compositions comprising long-chain organic molecules obtained from natural oils, particularly plant, bean, seed and nut oils, and their derivatives can be provided with increased oxygen stability by their combination with mixtur es of particular classes of antioxidants, particularly combinations of at least one synthetic free-radical terminating antioxidant. The stabilization combination is particularly effective in combination with long-chain oils having less than 5% methylene interrupted unsaturation. The long-chain oil m ay comprise a natural oil or wax. The long-chain oil may have a percent methyle ne interrupted unsaturation of less than 5%, less than 3%, or less than 1%. The emollient composition may have at least one supplemental additive, which is a reducing agent present in an amount of from 0.01 to 5% or more by weight of said long-chain oil and the free-radical terminating antioxidant is present in an amount of from 0.01 to 5% by weight of said long-chain oil. The compositi on preferably has the long-chain oil selected from the class consisting of Macadamia oil and its derivatives, Moringa oil and its derivatives, Babassu oil and its derivatives, and Meadowfoam and its derivatives, High Oleic Sunflower, and having a percentage methylene interrupted unsaturation of les s than 5.
All healthy volunteers are in this group. They receive 1g paracetamol orally. Saline-, urine-, venous blood and fingerprick samples will be collected at timely intervals.
This is a pilot study to assess the safety and tolerability, as well as the immune response rate, of mDC3 vaccine in patients with colorectal cancer.

Eligible patients that provide written informed consent will undergo apheresis to collect blood mononuclear cells for vaccine production approximately 1 week prior to vaccine infusion. Each study subject will receive cyclophosphamide 300mg/m\^2 intravenously 3 to 4 days prior to the vaccine dose to deplete regulatory T cells. For each vaccine dose, all subjects will receive autologous dendritic cells pulsed with mutated peptides. On Day 1, the subject will receive the primer vaccine dose; this will be followed by one booster vaccine dose approximately 8 weeks later. Peripheral blood will be taken weekly, and a second apheresis procedure will be performed at the end of study to monitor the immune response to the vaccine. Information will be gathered from usual clinic visits for approximately 1 year following the End of Treatment Study Visit to evaluate for disease progression.
Orthotic shorts will be made to measure for each participant, designed to provide some compression to the hips, pelvis and thighs and to provide support. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins and digitalis. Interference with the absorption of oral phosphate supplements has been observed with another positively charged bile acid sequestrant. Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation. The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been titrated to a maintenance level while the patient was taking cholestyramine resin. 

Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat-soluble vitamins such as A, D, E and K. When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered. 

SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
The invention provides a neutralizing monoclonal antibody B1G11 of a targeted fever with thrombocytopenia syndrome virus Gn glycoprotein and application thereof, belonging to the technical field of medicines. According to the invention, SFTSV Gn protein is used as an immunogen to immunize a mouse, and a high-efficiency neutralizing monoclonal antibody B1G11 of the specific targeting Gn is obtained through flow sorting and single B cell PCR. The monoclonal antibody B1G11 has very high in vitro neutralizing activity against SFTSV (as low as 0.04. Mu.g/mL for pseudo-toxic IC50 and as low as 0.4. Mu.g/mL for true-toxic IC 50). The monoclonal antibody B1G11 has application value for preventing and treating SFTSV infection, and can be used for preparing medicines for preventing and treating SFTSV infection and SFTSV detection products.
The invention relates to a preparation method of a traditional Chinese medicine for treating sore throat type acute glomerulonephritis, belonging to the technical field of preparation methods of traditional Chinese medicines. At present, hydrochlorothiazide is generally adopted for treating sore throat type acute glomerulonephritis, and the disadvantage is great side effect. The technical scheme adopted in the invention is as follows: taking fruticose breyniae, phymatopsis hastate, blackberry lily, puffball (collection cruise), calyx seu fructus physalis, subprostrate sophora, Chinese olive, manyleaf paris rhizome, potentilla discolor, radix berberidis, sticktight, Japanese cayratia herb, root of japanese raspberry, coffee senna, elephant hide, lophatherum gracile, butterflybush flower, mung bean, dandelion, red-spotted stonecrop, root of shortstalk slimptop meadowrue, fruticose breyniae, small-leaved desmodium, wintercherry, jeffersonia dubia, uniflower swisscentaury root, olive, small-leaved lemmaphyllum, creeping rostellularia herb, gamboges, androsace umbellate and liquorice, soaking the 32 kinds of traditional Chinese medicines in water, and decocting with slow fire, wherein the decocted liquid medicine is the traditional Chinese medicine for treating sore throat type acute glomerulonephritis. The traditional Chinese medicine for treating sore throat type acute glomerulonephritis has the advantages of short course of treatment and high cure rate. Assistant and guide are achieved so that the function is just right. Adverse reaction caused by Western medicine is avoided.
Mampalon penis product includes mampalon penis pill and mampalon penis wine. Homogenized mampalon penis powder is mixed with some Yang-strengthening Chinese medicinal materials powder and the mixture is honeyed and pelletized into mampalon penis pill. Mampalon penis and some optional Chinese medicinal materials with the function of promoting blood circulation to disperse blood clots, such as radix Ledebouriellae, notopterygium, Chinese angelica, etc. are socked in spirit to prepare rheumatism eliminating mampalon penis spirit. Mampalon penis and some optional Chinese medicinal materials with Yang-strengthening function, such as Morinda officinalis, Lycium chinense, pilose anlter, etc. are soaked in spirit to prepare Yang-strengthening mampalon penis spirit.
Clinical staff will apply Vamousse Spray 'n' Go during the baseline visit (Day 0) to fully coat the hair and scalp. The treatment will be left on for 8 hours, then standard at home shampoo will be used and rinsed off with warm water, followed by combing. At day 7, if live lice are still present, a repeat treatment will be administered.
PURPOSE: An anti-inflammatory composition containing Ficus erecta var. sieboldii leaf extract is provie to treat arthritis and to manufacture functional drink and drug. CONSTITUTION: An anti-inflammatory composition containing: Ficus erecta var. sieboldii leaf extract isolated using alcohol of C1-C5, acetone, hexane, ethyl acetatae, dichloromethane, water, or mixture solvent thereof; Ficus erecta var. sieboldii leaf extract obtained by fractioning Ficus erecta var. sieboldii leaf solid extract with mixture solvent of water and hexane, water and dichloromethane, or water and ethyl acetate; and Ficus erecta var. sieboldii leaf extract obtained by suspending solid extract in the water and fractioning with hexane, dichloromethane, ethyl acetate in order.
AIMS: Remnant cholesterol (RC) is the cholesterol content within triglyceride-rich lipoproteins. It promotes atherosclerotic cardiovascular disease beyond LDL cholesterol (LDL-C). The prognostic role of RC in patients with ST-segment elevation myocardial infarction (STEMI) is unknown. We aimed to estimate RC-related risk beyond LDL-C in patients with STEMI.
METHODS AND RESULTS: A total of 6602 consecutive patients with STEMI treated with primary percutaneous coronary intervention (PCI) from 1999 to 2016 were included. Remnant cholesterol was calculated as total cholesterol minus LDL-C minus HDL cholesterol. Adjusted Cox models were used to estimate the association between continuous RC levels and all-cause mortality, cardiovascular death, ischaemic stroke, and recurrent myocardial infarction (MI) at long-term (median follow-up of 6.0 years). Besides, discordance analyses were applied to examine the risk of the discordantly high RC (RC percentile rank minus LDL-C percentile rank > 10 units) compared with the discordantly low RC (LDL-C percentile rank minus RC percentile rank > 10 units). The concordance was defined as the percentile rank difference between RC and LDL-C ≤ 10 units. The median age of patients was 63 years [interquartile range (IQR) 54-72] and 74.8% were men. There were 2441, 1651, and 2510 patients in the discordantly low RC group, concordant group, and discordantly high RC group, respectively. All outcomes in the discordantly high RC group were higher than the other groups, and the event rate of all-cause mortality in this group was 31.87%. In the unadjusted analysis, the discordantly high RC was associated with increased all-cause mortality [hazard ratio (HR) 1.82, 95% confidence interval (CI) 1.63-2.04] and increased cardiovascular death (HR 1.79, 95% CI 1.55-2.06) compared with the discordantly low RC. In an adjusted model, RC was associated with higher all-cause mortality (HR 1.14, 95% CI 1.07-1.22). The discordantly high RC was associated with increased all-cause mortality (adjusted HR 1.55, 95% CI 1.37-1.75) and increased cardiovascular death (adjusted HR 1.47, 95% CI 1.25-1.72) compared with the discordantly low RC. There were no associations between RC and ischaemic stroke or recurrent MI.
CONCLUSION: In patients with STEMI treated with primary PCI, elevated RC levels beyond LDL-C and discordantly high RC were independently associated with increased all-cause mortality.
Cold Sores (Herpes Labialis): Valacyclovir tablets, USP are indicated for treatment of cold sores (herpes labialis). The efficacy of valacyclovir tablets, USP initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established.

Genital Herpes: Initial Episode: Valacyclovir tablets, USP are indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 72 hours after the onset of signs and symptoms has not been established. 

Recurrent Episodes: Valacyclovir tablets, USP are indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 24 hours after the onset of signs and symptoms has not been established.

Suppressive Therapy: Valacyclovir tablets, USP are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-infected adults. The efficacy and safety of valacyclovir tablets, USP for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-infected patients have not been established.

Reduction of Transmission: Valacyclovir tablets, USP are indicated for the reduction of transmission of genital herpes in immunocompetent adults. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes beyond 8 months in discordant couples has not been established. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] Sexually Transmitted Diseases Treatment Guidelines).

Herpes Zoster: Valacyclovir tablets, USP are indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of valacyclovir tablets, USP when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir tablets, USP for treatment of disseminated herpes zoster have not been established.
Antiviral proteins phytolaccin1 and phytolaccin2 were isolated from the higher plant Phytolaccin americana using the technique of immunoaffinity chromatography. Phytolaccin proteins were purified to apparent homogeneity in a rapid and efficient chromatographic procedure utilizing immobilized monospecific anti-phytolaccin antibodies. Immunoaffinity-purified phytolaccin1 and phytolaccin2 were determined by denaturing gel electrophoresis to be of approximately 25,600 and 28,400 daltons, respectively. The two immunoaffinity-purified proteins were equally potent inhibitors of eukaryotic cell-free protein biosynthesis and exhibited mostly similar high-order UV derivative spectra. Antibodies against phytolaccin1 and phytolaccin2 did not cross-react with the heterologous antigen, indicating a structural dissimilarity between the two phytolaccin proteins. Phytolaccin1 protein, purified according to the process of the invention, has been found to be an effective antiviral agent for the treatment of Herpes Simplex type II infections.
Flaviviruses represent an increasing global public health issue, with no prophylactic and therapeutic formulations currently available for many of them. The combination of factors such as evolutionary change, global warming and wide range of animal hosts suggest the possible occurrence of  Flavivirus  strains with greater distribution and human pathogenicity. There is, thus, a need for greater understanding of viral protein sequences that function in the human immune responses. The evolutionary diversity of the reported sequences of major flaviviruses, such as dengue virus, yellow fever virus, japanese encephalitis virus, and West Nile virus were analyzed with a combination of experimental and bioinformatics methodologies. The analysis of all reported sequences revealed that these species-specific peptide tags are highly conserved and are potential T-cell epitopes due to correspondence to known or predicted epitopes. These peptide tags have direct relevance to the development of new-generation vaccines and diagnostic applications.
The active control group will receive hand holding by the same trained nurse in addition to standard ICU care. The same hand hygiene and environmental adjustments will be made as for those receiving massage. Patients will have their hands held for 5-10 seconds and unscented hypoallergenic cream applied to both hands. Then, the interventionist will hold each of the patients' hand in her hand for ten minutes without performing any tissue manipulation. The hand holding procedure will last for a total of 20 minutes.
Ischemia-reperfusion (I/R) injury, a multifaceted pathological process, occurs when the prolongation of reperfusion duration triggers ferroptosis-mediated myocardial damage. Isoliquiritigenin (ISL), a single flavonoid from licorice, exhibits a wide range of pharmacological impacts, but its function in ferroptosis caused by myocardial I/R injury remains unclear. This study delved into the protective effect of ISL on myocardial I/R injury-induced ferroptosis and its mechanism. Neonatal mouse cardiomyocytes (NMCM) underwent hypoxia/reoxygenation (H/R) to simulate the pathological process of myocardial I/R. ISL significantly attenuated H/R-triggered production of reactive oxygen species in NMCM, reduced the expression of malondialdehyde and the activity of lactate dehydrogenase, enhanced superoxide dismutase and catalase activity, and increased the expression of nuclear factor E2-related factor 2 (Nrf2) and its downstream heme oxygenase 1 (HO-1), thereby mitigating oxidative stress damage. CCK8 experiment revealed that the ferroptosis inhibitor Ferrostatin-1 significantly improved myocardial cell viability after 24 h of reoxygenation, and ISL treatment showed a similar effect. ISL reduced intracellular free iron accumulation, up-regulated glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) expression, and inhibited lipid peroxidation accumulation, thereby alleviating ferroptosis. The Nrf2-specific inhibitor ML385 counteracted ISL's defensive role against H/R-triggered oxidative stress damage and ferroptosis. In vivo experiments further confirmed that by regulating the translocation of Nrf2 into the nucleus, ISL treatment increased the levels of HO-1, GPX4, and SLC7A11, inhibited the expression of ACSL4, Drp1 to exert the antioxidant role, alleviated mitochondrial damage, and ferroptosis, ultimately reducing myocardial infarction area and injury induced by I/R. ML385 nearly abolished ISL's protective impact on the I/R model by inhibiting Nrf2 function. In summary, ISL is capable of mitigating oxidative stress, mitochondrial damage, and cardiomyocyte ferroptosis caused by I/R, thereby reducing myocardial injury. A key mechanism includes triggering the Nrf2/HO-1/SLC7A11/GPX4 pathway to prevent oxidative stress damage and cardiomyocyte ferroptosis caused by I/R.
PURPOSE: A Scutellaria baicalensis fermentation and a composition containing the same for enhancing an antibacterial property and immunity are provided to efficiently prevent diseases and to enhance immunity by being applied to various fields such as food compositions or pharmaceutical compositions as well as feed compositions and to prevent toxicity or resistance with safety. CONSTITUTION: A Scutellaria baicalensis fermentation is prepared by fermenting a Scutellaria baicalensis extract with lactic acid bacteria. The lactic acid bacteria are L. plantarum VITA-L02 (KCTC 12030BP). A method for preparing the fermentation comprises the steps of: extracting Scutellaria baicalensis and preparing the Scutellaria baicalensis extract; and inoculating the extract with the lactic acid bacteria and fermenting. A feed composition, a pharmaceutical composition, and a food composition for enhancing an antibacterial property and immunity contain the fermentation. [Reference numerals] (AA) Change of an E.coli group; (BB) Control group; (CC) Scutellaria baicalensis; (DD) Scutellaria baicalensis fermentation; (EE) 0 week; (FF) 1 week; (GG) 2 weeks; (HH) 3 weeks; (II) 4 weeks
Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline. The stimulator to be used will be the "Chattanooga Ionto ISO 13485". Stimulation will be performed for 5 days, one time per day.
Children with autism spectrum disorders (ASD) may have severe behavior problems, including aggression, self-injurious behaviors, severe and persistent stereotypic behaviors, and extreme hyperactivity, which limit their ability to function socially and academically and are often disruptive to family life as well. Cannabidiol (CBD), a compound originally derived from the cannabis plant but without the psychoactive effects found in cannabis, has been shown to be safe and effective in the treatment of children with severe epilepsy. Two non-controlled studies using CBD from local sources have demonstrated improvements in behavior in children with autism. Parents of autistic children have been using CBD products in an unregulated fashion with unknown dosing with anecdotal reports of improved behavior. This study will use EPIDIOLEX (EPX), a purified CBD oral solution that was FDA approved in June 2018 to treat severe forms of pediatric epilepsy. Study subjects will be 30 boys between 7 and 14 years of age with autism who have severe behavior problems. Every child will undergo baseline clinical evaluation, neuropsychological, behavioral, cognitive, and language testing, will have a test of brain wave activity (EEG) and a brain MRI scan. parents will complete questionnaires on various aspects of their child's behavior. Fifteen children will receive CBD for 8 weeks and 15 will receive a placebo that looks and tastes similar to the CBD (Period 1). All of the baseline tests and questionnaires will then be repeated. After a 4 week washout period, behavioral and cognitive tests and questionnaires will be repeated and then the treatments will be reversed (Period 2). At the end of 8 weeks, all of the baseline tests and questionnaires will be repeated. Study personnel and parents will be blinded to the treatment status of each child. Statistical analyses will be used to determine whether there are significant differences between baseline testing and results after placebo or CBD treatment. Types and severities of adverse events will be tracked to provide information about the safety and tolerability of CBD in this population. If CBD is found to be safe and effective in treating the behavioral problems associated with autism, this would be a major new tool in the treatment of those children that could lead to improved functioning and quality of life for the affected individuals and their families.
The patient receives five sessions (weekly) of real acupuncture treatment in the acupuncture points LI4, S6, S7 and SI18. Each session lasts 30 minutes.
Lifetime carcinogenicity studies were performed in rats and mice at bupropion doses up to 300 and 150 mg/kg/day, respectively. These doses are approximately 7 and 2 times the MRHD, respectively, on a mg/m2 basis. In the rat study there was an increase in nodular proliferative lesions of the liver at doses of 100 to 300 mg/kg/day (approximately 2 to 7 times the MRHD on a mg/m2 basis); lower doses were not tested. The question of whether or not such lesions may be precursors of neoplasms of the liver is currently unresolved. Similar liver lesions were not seen in the mouse study, and no increase in malignant tumors of the liver and other organs was seen in either study.

Bupropion produced a positive response (2 to 3 times control mutation rate) in 2 of 5 strains in the Ames bacterial mutagenicity assay. Bupropion produced an increase in chromosomal aberrations in 1 of 3 in vivo rat bone marrow cytogenetic studies. 

A fertility study in rats at doses up to 300 mg/kg/day revealed no evidence of impaired fertility.